Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer

Little is known on the long-lasting humoral response and the T cell activation induced by SARS-CoV-2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-CoV-2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordry, Natacha, Addeo, Alfredo, Jaksic, Cyril, Dutoit, Valérie, Roux-Lombard, Pascale, Shah, Dimpy P., Shah, Pankil K., Gayet-Ageron, Angèle, Friedlaender, Alex, Bugeia, Sébastien, Gutknecht, Garance, Battagin, Anna, Di Marco, Maragrazia, Simand, Pierre-Francois, Labidi-Galy, Intidhar, Fertani, Sarah, Sandoval, José, Dietrich, Pierre-Yves, Mach, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704782/
https://www.ncbi.nlm.nih.gov/pubmed/34977496
http://dx.doi.org/10.1016/j.isci.2021.103699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704782/
https://www.ncbi.nlm.nih.gov/pubmed/34977496
http://dx.doi.org/10.1016/j.isci.2021.103699

Ejemplares similares